Search Results
May 21, 2026, 06:00 ET Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates
More news about: Innovent Biologics
May 20, 2026, 11:30 ET The Big Timber Auction: Bar None Auction's Largest Logging and Forestry Equipment Auction - Coming Soon to Woodburn, Oregon
units.Crawler Dozers: CAT D7E, D7G, D6M, D6D, D5K2 XL, D4K2 LGP, John Deere 650K and more.Compaction Equipment: Dynapac CA3500PD, Cat CS433B Smooth Drum, Sakai SV91TF Padfoot and more.Additional Machinery & Support Equipment: Tracked Dumpers, Grinders, Whole
More news about: Bar None Auction
May 20, 2026, 10:05 ET CREATV BIO STUDIES PRESENTED AT AACR ANNUAL MEETING SHOWING IMPORTANCE OF MONITORING PD-L1, MITOTIC CTCs and CAMLs IN BLOOD
4. Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC Abstract: 1033Key Finding: Monitoring PD-L1 expression on CTCs and CAMLs identifies PD-L1 upregulation after treatment with
More news about: Creatv MicroTech, Inc.
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
carcinoma (RCC) who received lenvatinib plus pembrolizumab (KEYTRUDA®), Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, versus sunitinib (multiple receptor TKI) in the first-line setting. These findings build on the body of evidence supporting the established
More news about: Eisai Inc.
May 20, 2026, 03:37 ET BioArctic Interim Report for the period January - March 2026
adapted to both patients and healthcare systems.Strengthened scientific and clinical evidence for LeqembiAt the international AD/PD conference in March, new long-term and real-world clinical data for Leqembi were presented. These showed that patients choose to remain on treatment
More news about: BioArctic
May 20, 2026, 03:30 ET Silicon on Insulator Market Outlook 2031: USD 3.96 Billion Opportunity, with Consumer Electronics Holding 41.43% Market Share, Reports Mordor Intelligence
InsightsBy SOI PlatformFully Depleted Silicon on Insulator (FD-SOI)Partially Depleted Silicon on Insulator (PD-SOI)Power-SOIOther TypesBy Wafer SizeLess Than or Equal To 200 mm201 mm and AboveBy
More news about: Mordor Intelligence Private Limited
May 20, 2026, 03:30 ET BioArctic Interim Report for the period January - March 2026
adapted to both patients and healthcare systems.Strengthened scientific and clinical evidence for LeqembiAt the international AD/PD conference in March, new long-term and real-world clinical data for Leqembi were presented. These showed that patients choose to remain on treatment
More news about: BioArctic
May 19, 2026, 20:00 ET Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
May 19, 2026, 09:39 ET Parkinson's Foundation Invests Nearly $600K in Innovative Care Grants
improving care systems to help people with PD live better lives, today."The Paul Oreffice Innovations in Care Awards program is a result of the Parkinson's Foundation National Roundtable on Care and Innovation held earlier last year, which brought together PD experts across several sectors to establish
More news about: Parkinson's Foundation
May 19, 2026, 08:30 ET First Responders Children's Foundation Marks 25 Years of Impact at Anniversary Gala in New York City
Jong Charitable Foundation.The gala event would not have been possible without partnership support from NYPD, FDNY, MTA Police, Port Authority PD, NY State Police, Metro-North Railroad, and Grand Central Terminal.
More news about: First Responders Children's Foundation
May 19, 2026, 08:30 ET Greenland Mines Brings Skaergaard to EIT RawMaterials Summit 2026 in Brussels
converted to Mineral Reserves or that an economically viable mining operation can be established.¹ Based on cumulative contained ounces of Au, Pd, and Pt in the 2022 NI 43-101 Technical Report MRE and February 2026 metal prices. Gross in-situ contained metal value only; excludes all mining, processing,
More news about: Greenland Mines Ltd
May 19, 2026, 07:00 ET BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in 2027.
More news about: BioLineRx Ltd.; Hemispherian AS
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist
More news about: Nanjing Leads Biolabs Co., Ltd.
May 18, 2026, 20:00 ET Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance
More news about: Accro Bioscience Inc.
May 18, 2026, 20:00 ET Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
TED models, the molecule effectively suppressed the expansion of orbital adipose and muscular tissues. In Pharmacokinetics & Pharmacodynamics (PK/PD) Studies in Non-Human Primates (NHPs), IBI3031 demonstrated a superior PK profile compared to existing SoCs. These results suggest a potential for extended
More news about: Innovent Biologics
May 18, 2026, 14:22 ET B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
billion as of early 2026.[6] On January 12, 2026, Summit announced a clinical trial collaboration with GSK plc to evaluate ivonescimab — Summit's lead PD-1 / VEGF bispecific antibody — in combination with GSK's novel investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (also known
More news about: USA News Group
May 18, 2026, 12:30 ET OMNY Health Surpasses 175 Million Patient Milestone; Launches Oncology Product Suite to Solve Complex Real-World Evidence Gaps
Variables: Direct access to granular data including tumor staging, treatment plans, mutation data, and molecular biomarkers (e.g., EGFR, ALK, PD-L1).Auditability & Provenance: A transparent digital "paper trail" connects every data point to its source clinical event, ensuring
More news about: OMNY Health
May 18, 2026, 12:00 ET Magellan: El único colegio laico e independiente de EE. UU. con programa IB completo y bilingüe desde preescolar hasta 12.º grado
Magellan International School recibió oficialmente la autorización para ofrecer el Programa del Diploma (PD) del Bachillerato Internacional (IB), consolidando así su designación como un Colegio Continuo del IB completo.
More news about: Magellan International School
May 18, 2026, 09:15 ET Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
disease markets," said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics. "With encouraging early Phase 1 PK, PD, and safety data, the advancement of BBT002 into patients with CRSwNP, and multiple upcoming clinical milestones including topline data from our ongoing
More news about: Bambusa Therapeutics, Inc.
May 18, 2026, 08:36 ET Leading the Way in Mobility Support for the Parkinson's Community at the World Parkinson's Conference
Dance for PD, and
More news about: Urban Poling Inc.
May 18, 2026, 08:00 ET Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit
More news about: Bio-Thera Solutions, Ltd
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
of adult patients with locally advanced or mUC who:have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, orare ineligible for cisplatin-containing chemotherapy and have previously
More news about: Astellas Pharma Inc.
May 18, 2026, 07:00 ET Compugen Reports First Quarter 2026 Results
evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license
More news about: Compugen Ltd.
May 17, 2026, 20:00 ET LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
(Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.
More news about: LOTTE Biologics
May 17, 2026, 20:00 ET LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
(Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.
More news about: LOTTE Biologics